Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2014-12-31

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-14-0819PMID 25552366PMCID PMC4456253
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy.

  2013cited by this paper
• STAT5A/B gene locus undergoes amplification during human prostate cancer progression.

  2013cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Re: Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Pharmacologic Inhibition of Jak2–Stat5 Signaling By Jak2 Inhibitor AZD1480 Potently Suppresses Growth of Both Primary and Castrate-Resistant Prostate Cancer

  2013cited by this paper
• Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo

  2011cited by this paper
• The changing therapeutic landscape of castration-resistant prostate cancer

  2011cited by this paper
• The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

  2010cited by this paper
• Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth.

  2010cited by this paper
• Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo.

  2010cited by this paper
• BRCA1 16 years later: nuclear import and export processes

  2010cited by this paper
• N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells.

  2010cited by this paper
• The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor.

  2009cited by this paper
• Steroid Hormone Transforming Aldo‐Keto Reductases and Cancer

  2009cited by this paper
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

  2009cited by this paper
• Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.

  2008cited by this paper
• Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells.

  2008influential reference
• Transcription Factor Signal Transducer and Activator of Transcription 5 Promotes Growth of Human Prostate Cancer Cells In vivo

  2008influential reference
• Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.

  2008cited by this paper
• E6-associated protein (E6-AP) is a dual function coactivator of steroid hormone receptors

  2008cited by this paper
• Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.

  2007cited by this paper
• Degradation and beyond: Control of androgen receptor activity by the proteasome system

  2006cited by this paper
• Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival

  2006cited by this paper
• Activation of Signal Transducer and Activator of Transcription-5 in Prostate Cancer Predicts Early Recurrence

  2005cited by this paper
• Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer

  2005cited by this paper
• Regulation of BRCA1, BRCA2 and BARD1 intracellular trafficking

  2005cited by this paper
• Signal transducer and activator of transcription-5 activation and breast cancer prognosis.

  2004cited by this paper
• An Androgen Receptor NH2-terminal Conserved Motif Interacts with the COOH Terminus of the Hsp70-interacting Protein (CHIP)*

  2004cited by this paper
• Activation of Signal Transducer and Activator of Transcription 5 in Human Prostate Cancer Is Associated with High Histological Grade

  2004cited by this paper
• Endocrine mechanisms of disease: Expression and degradation of androgen receptor: mechanism and clinical implication.

  2003cited by this paper
• Expression and Degradation of Androgen Receptor: Mechanism and Clinical Implication

  2003cited by this paper
• Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells.

  2003cited by this paper
• Inhibition of Transcription Factor Stat5 Induces Cell Death of Human Prostate Cancer Cells*

  2003cited by this paper
• Phosphorylation‐dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase

  2002cited by this paper
• Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.

  2002cited by this paper
• Molecular biology of the androgen receptor.

  2002cited by this paper
• Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium.

  2002cited by this paper
• Signalling: STATs: transcriptional control and biological impact

  2002cited by this paper
• Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor*

  2002cited by this paper
• PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro.

  2002cited by this paper
• α-methylacyl-CoA racemase: A new molecular marker for prostate cancer

  2002cited by this paper
• Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.

  2001cited by this paper
• Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

  1999cited by this paper
• Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2.

  1999cited by this paper
• STATs and gene regulation.

  1997cited by this paper
• Two Androgen Response Regions Cooperate in Steroid Hormone Regulated Activity of the Prostate-specific Antigen Promoter (*)

  1996cited by this paper
• In vivo amplification of the androgen receptor gene and progression of human prostate cancer

  1995cited by this paper
• Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones.

  1992cited by this paper
• Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer.

  1982influential reference
• Flutamide. Mechanism of action of a new nonsteroidal antiandrogen.

  1976cited by this paper

• Stat5 induces androgen receptor (AR) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling

  2024influential citation
• Impact of STAT Proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized Prostate Cancer

  2021cites this paper
• Monovalent protein-degraders - Insights and future perspectives.

  2020cites this paper
• Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo

  2020cites this paper
• Prolactin: A hormone with diverse functions from mammary gland development to cancer metastasis.

  2020cites this paper
• CYTOKINES, JAK-STAT SIGNALING AND RADIATION-INDUCED DNA REPAIR IN SOLID TUMORS: NOVEL OPPORTUNITIES FOR RADIATION THERAPY.

  2020cites this paper
• Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications

  2019cites this paper
• Dihydrotestosterone promotes kidney cancer cell proliferation by activating the STAT5 pathway via androgen and glucocorticoid receptors

  2019cites this paper
• Drosophila Jak/STAT Signaling: Regulation and Relevance in Human Cancer and Metastasis

  2018cites this paper
• Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients

  2018cites this paper
• Androgen receptor: what we know and what we expect in castration-resistant prostate cancer

  2018cites this paper
• Interleukin-6 and prostate cancer: Current developments and unsolved questions.

  2017cites this paper
• Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.

  2017cites this paper
• A global view of regulatory networks in lung cancer: An approach to understand homogeneity and heterogeneity.

  2017cites this paper
• ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development

  2017cites this paper
• Erratum: ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development

  2017cites this paper
• Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles

  2016influential citation
• Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.

  2015cites this paper
• TUMORIGENESIS AND NEOPLASTIC PROGRESSION Jak 2-Stat 5 a / b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer

  year unknowncites this paper